Cargando…

HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major health problem in the western world. Despite a widespread implementation of integrated care programs there are still patients with poorly controlled T2DM. Shared goal setting within the process of Shared Decision Making (SDM) may increase patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Sara, Pentzek, Michael, Altiner, Attila, Daubmann, Anne, Drewelow, Eva, Helbig, Christian, Löffler, Christin, Löscher, Susanne, Wegscheider, Karl, Abholz, Heinz-Harald, Wilm, Stefan, Wollny, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182591/
https://www.ncbi.nlm.nih.gov/pubmed/37173620
http://dx.doi.org/10.1186/s12875-023-02067-9
_version_ 1785041786885898240
author Santos, Sara
Pentzek, Michael
Altiner, Attila
Daubmann, Anne
Drewelow, Eva
Helbig, Christian
Löffler, Christin
Löscher, Susanne
Wegscheider, Karl
Abholz, Heinz-Harald
Wilm, Stefan
Wollny, Anja
author_facet Santos, Sara
Pentzek, Michael
Altiner, Attila
Daubmann, Anne
Drewelow, Eva
Helbig, Christian
Löffler, Christin
Löscher, Susanne
Wegscheider, Karl
Abholz, Heinz-Harald
Wilm, Stefan
Wollny, Anja
author_sort Santos, Sara
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major health problem in the western world. Despite a widespread implementation of integrated care programs there are still patients with poorly controlled T2DM. Shared goal setting within the process of Shared Decision Making (SDM) may increase patient’s compliance and adherence to treatment regimen. In our secondary analysis of the cluster-randomized controlled DEBATE trial, we investigated if patients with shared vs. non-shared HbA1c treatment goal, achieve their glycemic goals. METHODS: In a German primary care setting, we collected data before intervention at baseline, 6, 12 and 24 months. Patients with T2DM with an HbA1c ≥ 8.0% (64 mmol/mol) at the time of recruitment and complete data at baseline and after 24 months were eligible for the presented analyses. Using a generalized estimating equation analysis, we analysed the association between the achievement of HbA1c goals at 24 months based on their shared vs. non-shared status, age, sex, education, partner status, controlled for baseline HbA1c and insulin therapy. RESULTS: From N = 833 recruited patients at baseline, n = 547 (65.7%) from 105 General Practitioners (GPs) were analysed. 53.4% patients were male, 33.1% without a partner, 64.4% had a low educational level, mean age was 64.6 (SD 10.6), 60.7% took insulin at baseline, mean baseline HbA1c was 9.1 (SD 1.0). For 287 patients (52.5%), the GPs reported to use HbA1c as a shared goal, for 260 patients (47.5%) as a non-shared goal. 235 patients (43.0%) reached the HbA1c goal after two years, 312 patients (57.0%) missed it. Multivariable analysis shows that shared vs. non-shared HbA1c goal setting, age, sex, and education are not associated with the achievement of the HbA1c goal. However, patients living without a partner show a higher risk of missing the goal (p = .003; OR 1.89; 95% CI 1.25–2.86). CONCLUSIONS: Shared goal setting with T2DM patients targeting on HbA1c-levels had no significant impact on goal achievement. It may be assumed, that shared goal setting on patient-related clinical outcomes within the process of SDM has not been fully captured yet. TRIAL REGISTRATION: The trial was registered at ISRCTN registry under the reference ISRCTN70713571. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12875-023-02067-9.
format Online
Article
Text
id pubmed-10182591
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101825912023-05-14 HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial Santos, Sara Pentzek, Michael Altiner, Attila Daubmann, Anne Drewelow, Eva Helbig, Christian Löffler, Christin Löscher, Susanne Wegscheider, Karl Abholz, Heinz-Harald Wilm, Stefan Wollny, Anja BMC Prim Care Research BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major health problem in the western world. Despite a widespread implementation of integrated care programs there are still patients with poorly controlled T2DM. Shared goal setting within the process of Shared Decision Making (SDM) may increase patient’s compliance and adherence to treatment regimen. In our secondary analysis of the cluster-randomized controlled DEBATE trial, we investigated if patients with shared vs. non-shared HbA1c treatment goal, achieve their glycemic goals. METHODS: In a German primary care setting, we collected data before intervention at baseline, 6, 12 and 24 months. Patients with T2DM with an HbA1c ≥ 8.0% (64 mmol/mol) at the time of recruitment and complete data at baseline and after 24 months were eligible for the presented analyses. Using a generalized estimating equation analysis, we analysed the association between the achievement of HbA1c goals at 24 months based on their shared vs. non-shared status, age, sex, education, partner status, controlled for baseline HbA1c and insulin therapy. RESULTS: From N = 833 recruited patients at baseline, n = 547 (65.7%) from 105 General Practitioners (GPs) were analysed. 53.4% patients were male, 33.1% without a partner, 64.4% had a low educational level, mean age was 64.6 (SD 10.6), 60.7% took insulin at baseline, mean baseline HbA1c was 9.1 (SD 1.0). For 287 patients (52.5%), the GPs reported to use HbA1c as a shared goal, for 260 patients (47.5%) as a non-shared goal. 235 patients (43.0%) reached the HbA1c goal after two years, 312 patients (57.0%) missed it. Multivariable analysis shows that shared vs. non-shared HbA1c goal setting, age, sex, and education are not associated with the achievement of the HbA1c goal. However, patients living without a partner show a higher risk of missing the goal (p = .003; OR 1.89; 95% CI 1.25–2.86). CONCLUSIONS: Shared goal setting with T2DM patients targeting on HbA1c-levels had no significant impact on goal achievement. It may be assumed, that shared goal setting on patient-related clinical outcomes within the process of SDM has not been fully captured yet. TRIAL REGISTRATION: The trial was registered at ISRCTN registry under the reference ISRCTN70713571. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12875-023-02067-9. BioMed Central 2023-05-13 /pmc/articles/PMC10182591/ /pubmed/37173620 http://dx.doi.org/10.1186/s12875-023-02067-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Santos, Sara
Pentzek, Michael
Altiner, Attila
Daubmann, Anne
Drewelow, Eva
Helbig, Christian
Löffler, Christin
Löscher, Susanne
Wegscheider, Karl
Abholz, Heinz-Harald
Wilm, Stefan
Wollny, Anja
HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
title HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
title_full HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
title_fullStr HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
title_full_unstemmed HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
title_short HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
title_sort hba1c as a shared treatment goal in type 2 diabetes? a secondary analysis of the debate trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182591/
https://www.ncbi.nlm.nih.gov/pubmed/37173620
http://dx.doi.org/10.1186/s12875-023-02067-9
work_keys_str_mv AT santossara hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT pentzekmichael hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT altinerattila hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT daubmannanne hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT dreweloweva hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT helbigchristian hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT lofflerchristin hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT loschersusanne hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT wegscheiderkarl hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT abholzheinzharald hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT wilmstefan hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial
AT wollnyanja hba1casasharedtreatmentgoalintype2diabetesasecondaryanalysisofthedebatetrial